Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ITGAV_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ITGAV_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ITGAV_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ITGAV_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ITGAV_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ITGAV_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ITGAV_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ITGAV_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001905812 | Liver | Cirrhotic | viral life cycle | 148/4634 | 317/18723 | 1.12e-17 | 1.64e-15 | 148 |
GO:004440312 | Liver | Cirrhotic | biological process involved in symbiotic interaction | 131/4634 | 290/18723 | 2.00e-14 | 1.84e-12 | 131 |
GO:20012347 | Liver | Cirrhotic | negative regulation of apoptotic signaling pathway | 102/4634 | 224/18723 | 8.40e-12 | 5.60e-10 | 102 |
GO:009719112 | Liver | Cirrhotic | extrinsic apoptotic signaling pathway | 97/4634 | 219/18723 | 1.82e-10 | 9.11e-09 | 97 |
GO:200123612 | Liver | Cirrhotic | regulation of extrinsic apoptotic signaling pathway | 72/4634 | 151/18723 | 7.80e-10 | 3.62e-08 | 72 |
GO:005170112 | Liver | Cirrhotic | biological process involved in interaction with host | 88/4634 | 203/18723 | 4.55e-09 | 1.82e-07 | 88 |
GO:00521267 | Liver | Cirrhotic | movement in host environment | 75/4634 | 175/18723 | 1.08e-07 | 3.07e-06 | 75 |
GO:003158912 | Liver | Cirrhotic | cell-substrate adhesion | 128/4634 | 363/18723 | 4.10e-06 | 6.90e-05 | 128 |
GO:005123511 | Liver | Cirrhotic | maintenance of location | 117/4634 | 327/18723 | 4.78e-06 | 7.86e-05 | 117 |
GO:20012377 | Liver | Cirrhotic | negative regulation of extrinsic apoptotic signaling pathway | 44/4634 | 97/18723 | 7.61e-06 | 1.15e-04 | 44 |
GO:000689811 | Liver | Cirrhotic | receptor-mediated endocytosis | 91/4634 | 244/18723 | 8.13e-06 | 1.22e-04 | 91 |
GO:003444612 | Liver | Cirrhotic | substrate adhesion-dependent cell spreading | 47/4634 | 108/18723 | 1.48e-05 | 2.05e-04 | 47 |
GO:000722911 | Liver | Cirrhotic | integrin-mediated signaling pathway | 46/4634 | 107/18723 | 2.66e-05 | 3.42e-04 | 46 |
GO:00439037 | Liver | Cirrhotic | regulation of biological process involved in symbiotic interaction | 34/4634 | 72/18723 | 2.86e-05 | 3.64e-04 | 34 |
GO:000716011 | Liver | Cirrhotic | cell-matrix adhesion | 85/4634 | 233/18723 | 4.06e-05 | 4.83e-04 | 85 |
GO:001087611 | Liver | Cirrhotic | lipid localization | 147/4634 | 448/18723 | 6.24e-05 | 7.12e-04 | 147 |
GO:0042157 | Liver | Cirrhotic | lipoprotein metabolic process | 53/4634 | 135/18723 | 1.32e-04 | 1.29e-03 | 53 |
GO:00444097 | Liver | Cirrhotic | entry into host | 58/4634 | 151/18723 | 1.33e-04 | 1.30e-03 | 58 |
GO:00457857 | Liver | Cirrhotic | positive regulation of cell adhesion | 141/4634 | 437/18723 | 2.05e-04 | 1.89e-03 | 141 |
GO:00467187 | Liver | Cirrhotic | viral entry into host cell | 55/4634 | 144/18723 | 2.31e-04 | 2.11e-03 | 55 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0414520 | Cervix | CC | Phagosome | 47/1267 | 152/8465 | 3.95e-07 | 4.26e-06 | 2.52e-06 | 47 |
hsa052226 | Cervix | CC | Small cell lung cancer | 29/1267 | 92/8465 | 4.38e-05 | 3.09e-04 | 1.83e-04 | 29 |
hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa0491918 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa045147 | Cervix | CC | Cell adhesion molecules | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
hsa05418110 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0516319 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0451014 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481017 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa04145110 | Cervix | CC | Phagosome | 47/1267 | 152/8465 | 3.95e-07 | 4.26e-06 | 2.52e-06 | 47 |
hsa0522213 | Cervix | CC | Small cell lung cancer | 29/1267 | 92/8465 | 4.38e-05 | 3.09e-04 | 1.83e-04 | 29 |
hsa0516512 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa0491919 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa0451412 | Cervix | CC | Cell adhesion molecules | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ITGAV | SNV | Missense_Mutation | | c.1264G>A | p.Glu422Lys | p.E422K | P06756 | protein_coding | tolerated(0.45) | benign(0.003) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ITGAV | SNV | Missense_Mutation | | c.2729N>G | p.Leu910Trp | p.L910W | P06756 | protein_coding | tolerated(0.3) | probably_damaging(0.997) | TCGA-A8-A081-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ITGAV | SNV | Missense_Mutation | | c.147N>G | p.Phe49Leu | p.F49L | P06756 | protein_coding | deleterious(0.02) | probably_damaging(0.97) | TCGA-A8-A0AD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
ITGAV | SNV | Missense_Mutation | | c.323G>C | p.Arg108Thr | p.R108T | P06756 | protein_coding | deleterious(0.02) | benign(0.179) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
ITGAV | SNV | Missense_Mutation | | c.2281T>C | p.Ser761Pro | p.S761P | P06756 | protein_coding | tolerated(0.12) | probably_damaging(0.915) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ITGAV | SNV | Missense_Mutation | rs200733186 | c.2834N>G | p.Asn945Ser | p.N945S | P06756 | protein_coding | deleterious(0.04) | probably_damaging(0.991) | TCGA-OL-A97C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ITGAV | deletion | Frame_Shift_Del | | c.1682delG | p.Gly561AspfsTer2 | p.G561Dfs*2 | P06756 | protein_coding | | | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ITGAV | SNV | Missense_Mutation | | c.1990N>G | p.Gln664Glu | p.Q664E | P06756 | protein_coding | tolerated(1) | benign(0.224) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
ITGAV | SNV | Missense_Mutation | rs201231113 | c.298A>G | p.Ile100Val | p.I100V | P06756 | protein_coding | tolerated(0.12) | benign(0) | TCGA-ZJ-AAXT-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
ITGAV | SNV | Missense_Mutation | rs554897868 | c.2120N>A | p.Arg707His | p.R707H | P06756 | protein_coding | deleterious(0.01) | benign(0.028) | TCGA-4T-AA8H-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL2109621 | ABITUZUMAB | |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | antagonist | 348353648 | | |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | antagonist | CHEMBL429876 | CILENGITIDE | |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | VOLOCIXIMAB | VOLOCIXIMAB | |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | CYPATE | CYPATE | 22871580 |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | GLPG0187 | GLPG-0187 | |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | CNTO-95 | INTETUMUMAB | |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL2109623 | STX-100 | |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | Abituzumab | ABITUZUMAB | |
3685 | ITGAV | DRUGGABLE GENOME, CELL SURFACE, EXTERNAL SIDE OF PLASMA MEMBRANE | | CILENGITIDE | CILENGITIDE | 24095096 |